Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely.

Development 242

Development Bioequivalency Generic Drugs Production 242

Fossil Remedies

OCTOBER 16, 2022

When you launch a PCD pharma company , you have to do several preparations. In a pharma business, you have a distribution network like a pharma manufacturing company, pharma marketing company, C&F agents, wholesalers/distributors/stockiest, retailers, and pharmacies. Wholesale Drug License.

Licensing 52

Licensing Licensing Pharma Companies Manufacturing 52

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The company says in its IPO prospectus that it plans to list its shares on the Nasdaq Global Market under the ABCL ticker.

Drugs 111

Drugs Antibody FDA Approval Pharma Companies 111

Outsourcing Pharma

MARCH 2, 2023

A licensing agreement has been signed that will give Spanish pharma company, Ferrer, worldwide rights to a treatment for progressive supranuclear palsy (PSP).

Licensing 52

Licensing Licensing Pharma Companies Development 52

World of DTC Marketing

APRIL 12, 2021

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. We can’t continue to develop drugs the same way as we have done before.

Generic Drugs 187

Generic Drugs Manufacturing Drugs Production 187

pharmaphorum

JUNE 14, 2021

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 105

Drugs Pharma Companies Licensing Licensing 105

pharmaphorum

JANUARY 7, 2022

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery. The post Another big AI deal as Sanofi taps Exscientia for 15 new drugs appeared first on. Shortly after Amgen unveiled its $1.9

Drugs 110

Drugs Pharma Companies Medicine Licensing 110

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

pharmaphorum

FEBRUARY 12, 2021

Along with the $350 million upfront fee Sandoz is also pledging $150 million tied to sales performance in the deal, which excludes some rights to the drug in some markets including the US, China, Germany and Australia. The post Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs appeared first on.

Drugs 111

Drugs Sales Marketing Pharma Companies 111

pharmaphorum

MAY 20, 2022

In one of the first moves by a member of ATOM, Novartis has agreed to license rights to its tyrosine kinase inhibitor drug nilotinib – sold as Tasigna as a leukaemia treatment – to the UN-backed Medicines Patent Pool (MPP). The post Coalition aims to improve cancer drug access in poorer nations appeared first on.

Drugs 111

Drugs Medicine Licensing Licensing 111

pharmaphorum

JULY 14, 2022

The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97

pharmaphorum

AUGUST 4, 2020

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015.

Drugs 109

Drugs Clinical Trials Clinical Trials Pharma Companies 109

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Pharmaceutical Technology

AUGUST 1, 2022

The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines. As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. The US Food and Drug Administration (FDA) granted Eli Lilly’s Lartruvo (olaratumab) accelerated approval in 2016 for soft tissue sarcoma (STS). After this, Telix licenced the drug for $5m.

Development 130

Development Antibody Pharma Companies Licensing 130

Pharmaceutical Technology

AUGUST 12, 2022

In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.

Medicine 290

Medicine Production Generic Drugs Regulation 290

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The new drug has already cleared phase 1 single and multiple ascending dose and clinical pharmacology studies, according to Lilly.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

XTalks

MAY 29, 2024

This growth can be attributed to the rising cost of drugs, with prices for new drugs in the US having increased by 35 percent in 2023 compared to the previous year. The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 billion last year, up 4.2

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccine 52

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 119

Licensing Licensing Marketing Medicine 119

XTalks

AUGUST 21, 2023

The US Food and Drug Administration (FDA) has approved Ipsen’s groundbreaking Sohonos (palovarotene) capsules for the treatment of fibrodysplasia ossificans progressive (FOP), an ultra-rare bone disease. Sohonos, the first and only approved drug, offers hope to those battling the disease.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

Camargo

SEPTEMBER 23, 2020

Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

FEBRUARY 11, 2022

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. billion takeover of Clementia Pharma in 2019. billion of its revenues last year. billion of its revenues last year.

Sales 103

Sales Pharma Companies Branding Cosmetics 103

Pharmaceutical Technology

MARCH 31, 2023

According to a press release, the selected pharma companies will be allowed to produce long acting cabotegravir in 90 countries. MPP is a health organisation backed by the United Nations that facilitates access to drugs for low- and middle-income countries. This includes Apretude and the two oral drugs— Descovy and Truvada.

Medicine 130

Medicine Manufacturing Pharma Companies Licensing 130

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences. About the author.

Medicine 119

Medicine Pharma Companies Vaccination Vaccine 119

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 81

Antibody Licensing Licensing Protein 81

pharmaphorum

MAY 13, 2022

Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy Opdivo. The post BMS doubles down on BridgeBio alliance on SHP2 drugs appeared first on.

Drugs 59

Drugs Pharma Companies Medicine Licensing 59

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. In that respect it follows a similar model to Merck’s takeover of AmpTec, another CDMO that uses a PCR platform to make mRNA drugs, for an undisclosed sum last year.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

JUNE 2, 2021

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic dermatitis or eczema. . Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. Interest in the target has also prompted a flurry of licensing deals.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 64

Licensing Licensing Pharma Companies Drugs 64

Fossil Remedies

SEPTEMBER 23, 2022

PCD Pharma Franchise is a popular business model. It is a business arrangement in which a pharma company offers the rights of marketing and distribution to its franchise partner. The pharma company thus expands its business and reaches new regions. Check the market reputation and image of the company.

Pharma Companies 52

Pharma Companies Production Licensing Licensing 52

pharmaphorum

OCTOBER 7, 2021

The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company.

Vaccination 98

Vaccination Vaccine Manufacturing Packaging 98

pharmaphorum

JANUARY 20, 2022

The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. Lotus CEO, Petar Vazharov, said the partnership would ensure that the novel spray drug is accessible to patients in South East Asia.

Allergies 72

Allergies Marketing Production Manufacturing 72

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Medicine 52

pharmaphorum

NOVEMBER 16, 2022

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK retain the number one position, newly joined by Johnson & Johnson in second and AstraZeneca in third.

Medicine 105

Medicine Production Pharma Companies Licensing 105